- 101. Esophageal Speech
- [(eh-SOF-a-JEE-al) Speech produced by trapping air in the esophagus and forcing it out again. It is used after removal of a person's larynx (voice box). ( NCI )] (UMLS (NCI) C0037834) =Finding
| - 150. EST
- [Refers to Sequence Tagged Sites (EST) that are represented in mRNA. They are derived as 300-500 bp single-pass mRNA sequence reads from many of the genes expressed in a given tissue and/or at a given developmental stage. They represent a snapshot of gene expression in a given place or time. ( NCI )] (UMLS (NCI) C0600510) =Nucleic Acid, Nucleoside, or Nucleotide; Indicator, Reagent, or Diagnostic Aid
|
- 102. Esophageal Squamous Cell Carcinoma in situ
- [Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.)-2003 ( NCI )] (UMLS (NCI) C0854770) Esophageal Squamous Cell Carcinoma Stage 0;
Esophagus Squamous Cell Carcinoma in situ;
Oesophageal Squamous Cell Carcinoma Stage 0;
Squamous Cell Carcinoma in situ of Esophagus;
Squamous Cell Carcinoma in situ of the Esophagus;
Stage 0 Esophageal Squamous Cell Carcinoma;
Stage 0 Esophagus Squamous Cell Carcinoma;
Stage 0 Squamous Cell Carcinoma of Esophagus;
Stage 0 Squamous Cell Carcinoma of the Esophagus;
=Neoplastic Process | - 151. established cell line
- [ ] (UMLS (CSP) C0598089) =Cell ;
|
- 103. Esophageal Squamous Cell Carcinoma Stage I
- [Stage I includes: T1, N0, M0. T1: Tumor invades lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.)-2003 ( NCI )] (UMLS (NCI) C0854771) Oesophageal Squamous Cell Carcinoma Stage I;
Stage I Esophageal Squamous Cell Carcinoma;
Stage I Esophagus Squamous Cell Carcinoma;
Stage I Squamous Cell Carcinoma of Esophagus;
Stage I Squamous Cell Carcinoma of the Esophagus;
=Neoplastic Process | - 152. ester
- [organic compound formed by removal of water from an acid and an alcohol. ( CSP )] (UMLS (CSP) C0014898) =Organic Chemical ;
=carbonyl compound;
|
- 104. Esophageal Squamous Cell Carcinoma Stage II
- [Stage II includes: IIA: (T2, N0, M0); (T3, N0, M0); IIB: (T1, N1, M0); (T2, N1, M0). T1: Tumor invades lamina propria or submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.) - 2003 ( NCI )] (UMLS (NCI) C0854772) Oesophageal Squamous Cell Carcinoma Stage II;
Stage II Esophageal Squamous Cell Carcinoma;
Stage II Esophagus Squamous Cell Carcinoma;
Stage II Squamous Cell Carcinoma of Esophagus;
Stage II Squamous Cell Carcinoma of the Esophagus;
=Neoplastic Process | - 153. Ester Hydrolase
- [any of various enzymes that catalyze the hydrolysis of an ester to produce an alcohol and an acid. ( CSP )] (UMLS (NCI) C0014894) =Amino Acid, Peptide, or Protein; Enzyme =hydrolase;
=endodeoxyribonuclease;
endonuclease;
Endoribonuclease;
exonuclease;
lipase;
PDE;
phosphatase;
sulfatase;
carboxylesterase;
Carboxylic Ester Hydrolases;
choline esterase II;
deoxyribonuclease;
endonuclease;
|
- 105. Esophageal Squamous Cell Carcinoma Stage III
- [Stage III includes: (T3, N1, M0); (T4, Any N, M0). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.) - 2003 ( NCI )] (UMLS (NCI) C0854773) Oesophageal Squamous Cell Carcinoma Stage III;
Stage III Esophageal Squamous Cell Carcinoma;
Stage III Esophagus Squamous Cell Carcinoma;
Stage III Squamous Cell Carcinoma of Esophagus;
Stage III Squamous Cell Carcinoma of the Esophagus;
=Neoplastic Process | - 154. Esterase Gene
- [Esterase Genes encode Esterases that catalyze hydrolysis of ester bonds to produce alcohol and acid reaction products. (NCI) ( NCI )] (UMLS (NCI) C1333471) =Gene or Genome ;
|
- 106. Esophageal Squamous Cell Carcinoma Stage IV
- [Stage IV includes: IV: (Any T, Any N, M1); IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b). M1: Distant metastasis. Tumors of the lower thoracic esophagus. M1a: Metastasis in celiac lymph nodes. M1b: Other distant metastasis. Tumors of the mid-thoracic esophagus: M1a: Not applicable. M1b: Nonregional lymph nodes and/or other distant metastasis. Tumors of the upper thoracic esophagus. M1a: Metastasis in cervical nodes. M1b: Other distant metastasis (AJCC 6th ed.) - 2003 ( NCI )] (UMLS (NCI) C1142025) Metastatic Esophageal Squamous Cell Carcinoma;
Metastatic Esophagus Squamous Cell Carcinoma;
Metastatic Squamous Cell Carcinoma of Esophagus;
Metastatic Squamous Cell Carcinoma of the Esophagus;
Stage IV Esophageal Squamous Cell Carcinoma;
Stage IV Esophagus Squamous Cell Carcinoma;
Stage IV Squamous Cell Carcinoma of Esophagus;
Stage IV Squamous Cell Carcinoma of the Esophagus;
=Neoplastic Process | - 155. esterase inhibitor
- [substance or agent which suppresses, prevents or opposes the action of esterase. ( CSP )] (UMLS (CSP) C0596537) =Pharmacologic Substance ;
=enzyme inhibitor;
=cholinesterase inhibitor;
Phosphodiesterase Inhibitor |
- 107. Esophageal Squamous Intraepithelial Neoplasia
- (UMLS (NCI) C1333468) =Neoplastic Process
| - 156. esterification
- [process of converting an acid into an alkyl or aryl derivative; most frequently the process consists of the reaction of an acid with an alcohol in the presence of a trace of mineral acid as catalyst or the reaction of an acyl chloride with an alcohol; esterification can also be accomplished by enzymatic processes. ( CSP )] (UMLS (CSP) C0014895) =Natural Phenomenon or Process ;
=chemical reaction;
|
- 108. Esophageal Squamous Papilloma
- [A rare neoplasm arising from the distal third of the esophagus. Morphologically, it is characterized by the presence of fibrovascular cores covered by mature stratified squamous epithelium. Progression to squamous cell carcinoma is extremely rare. ( NCI )] (UMLS (NCI) C1333467) Esophagus Squamous Cell Papilloma;
Squamous Cell Papilloma of Esophagus;
Squamous Cell Papilloma of the Esophagus =Neoplastic Process | - 157. estetrol
- [A metabolite of ESTRIOL with a 15-alpha-hydroxyl group. Estetrol can be converted from estriol sulfate or DEHYDROEPIANDROSTERONE SULFATE by the fetal-placental unit. ( MSH )] (UMLS (CSP) C0014899) =Steroid; Hormone ;
|
- 109. Esophageal Ulcer
- (UMLS (NCI) C0151970) =Disease or Syndrome
| - 158. Estimate
- [To calculate approximately. ( NCI )] (UMLS (NCI) C0750572) Estimated =Quantitative Concept
|
- 110. Esophageal Undifferentiated Carcinoma
- (UMLS (NCI) C1333469) =Neoplastic Process ;
| - 159. Estimated (see comment)
- (UMLS (HL7) C1548591) =Idea or Concept =Quantity method;
|
- 111. esophageal varices
- [longitudinal venous varices at the lower end of the esophagus as a result of portal hypertension; they are superficial and liable to ulceration and massive bleeding. ( CSP )] (UMLS (CSP) C0014867) =Acquired Abnormality; Disease or Syndrome =Disease of esophagus;
blood vessel disorder;
gastrointestinal circulation disorder;
| - 160. Estimation
- (UMLS (NCI) C0681916) =Quantitative Concept ;
|
- 112. Esophageal varices in diseases classified elsewhere
- [ ] (UMLS (ICD9CM) C0155791) =Disease or Syndrome ;
| - 161. Estinyl
- (UMLS (NCI) C0699362) =Steroid; Pharmacologic Substance; Hormone ;
|
- 113. Esophageal Verrucous Carcinoma
- [A rare variant of esophageal squamous cell carcinoma. It is an exophytic, cauliflower-like or papillary mass that can arise in any part of the esophagus. This variant of squamous cell carcinoma grows slowly and invades locally, with a very low metastasizing potential. (WHO, 2000) — 2003 ( NCI )] (UMLS (NCI) C1333470) Verrucous Carcinoma of Esophagus;
Verrucous Carcinoma of the Esophagus;
=Neoplastic Process ;
| - 162. estivation
- [In certain living species, a period of dormancy during the summer months marked by decreased metabolism. ( MSH )] (UMLS (CSP) C0014906) =Organism Function
|
- 114. ESOPHAGEAL WEB INCISION
- [ ] (UMLS (ICD9CM) C0472948) =Therapeutic or Preventive Procedure
| - 163. Estrace
- (UMLS (NCI) C0699352) =Steroid; Pharmacologic Substance; Hormone ;
|
- 115. esophagectomy
- [(eh-sof-a-JEK-toe-mee) An operation to remove a portion of the esophagus. ( NCI )] (UMLS (NCI) C0085198) =Therapeutic or Preventive Procedure ;
| - 164. Estracyt
- (UMLS (NCI) C0014911) =Steroid; Pharmacologic Substance ;
|
- 116. esophagitis
- [Inflammation of the esophagus (the tube that carries food from the mouth to the stomach). ( NCI )] (UMLS (NCI) C0014868) =Disease or Syndrome ;
=Disease of esophagus;
=Esophagitis, Peptic;
| - 165. estradiol dehydrogenase
- [Enzymes that catalyze the oxidation of estradiol at the 17-hydroxyl group in the presence of NAD+ or NADP+ to yield estrone and NADH or NADPH. The 17-hydroxyl group can be in the alpha- or beta-configuration. EC 1.1.1.62 ( MSH )] (UMLS (CSP) C0014917) =Amino Acid, Peptide, or Protein; Enzyme ;
|
- 117. Esophagogastrectomy
- [Surgical removal of part or all of the esophagus, and part or all of the stomach. ( NCI )] (UMLS (NCI) C0192296) =Therapeutic or Preventive Procedure
| - 166. ESTRADIOL HEMIHYDRATE
- [The hemihydrate form of estradiol, the most potent, naturally produced estrogen. Estradiol hemihydrate diffuses through the cell membrane and binds to and subsequently activates the nuclear estrogen receptor found in the reproductive tract, breast, pituitary, hypothalamus, liver, and bone. The activated complex binds to the estrogen response element on the DNA and activates the transcription of genes involved in the functioning of the female reproductive system and secondary sex characteristics. ( NCI )] (UMLS (NCI) C0772181) =Steroid; Pharmacologic Substance; Hormone
|
- 118. esophagogastric junction
- [site of transition from the stratified squamous epithelium of the esophagus to the simple columnar epithelium of the cardia of the stomach. ( CSP )] (UMLS (CSP) C0014871) =Body Space or Junction ;
=Body System, Gastrointestinal;
| - 167. Estradiol Mustard
- [A conjugate of two agents, estradiol and an alkylating mustard (usually mechlorethamine or non-nitrogen mustard). Estramustine is one such agent (see Estramustine Phosphate Sodium). (NCI04) ( NCI )] (UMLS (NCI) C0059620) =Organic Chemical
|
- 119. esophagogastric junction disorder
- [condition in which there is a deviation from or interruption of the normal structure or function of the site of transition from the stratified squamous epithelium of the esophagus to the simple columnar epithelium of the cardia of the stomach. ( CSP )] (UMLS (CSP) C0596535) =Disease or Syndrome ;
=Gastrointestinal Diseases;
| - 168. Estradiol Phosphate Polymer
- [A synthetic long-acting polymer derivative of the female sex hormone estradiol. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Administration of polyestradiol phosphate leads to the marked decrease of testosterone levels and may exhibit a bone mass-preserving effect in patients with prostatic cancer. (NCI04) ( NCI )] (UMLS (NCI) C0071554) =Steroid; Pharmacologic Substance ;
=(17beta)-Estra-1,3,5(10)-triene-3,17-diol;
POLYESTRADIOL =POLYESTRADIOL PHOSPHATE 40 MG |
- 120. esophagogastroduodenoscopy
- [ ] (UMLS (CSP) C0079304) =Diagnostic Procedure ;
| - 169. ESTRADIOL VALERATE
- [The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04) ( NCI )] (UMLS (NCI) C0059623) =Steroid; Pharmacologic Substance; Hormone =(17beta)-Estra-1,3,5(10)-triene-3,17-diol;
=ESTRADIOL VALERATE 10 MG/ML;
ESTRADIOL VALERATE 20 MG/ML;
ESTRADIOL VALERATE 40 MG/ML;
ESTRADIOL VALERATE 5 MG;
ESTRADIOL VALERATE 8 MG/ML;
ESTRADIOL VALERATE 4 MG/ML |
- 121. ESOPHAGOGASTROPLASTY
- [ ] (UMLS (ICD9CM) C0192486) =Therapeutic or Preventive Procedure
| - 170. Estradiol/Zoledronate
- (UMLS (NCI) C1327809) =Therapeutic or Preventive Procedure ;
|
- 122. Esophagogastroscopy
- [Endoscopic examination of the esophagus and stomach. ( NCI )] (UMLS (NCI) C0192466) =Diagnostic Procedure
| - 171. Estramustine 17-(Dihydrogenphosphate) Disodium Salt
- [The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. ( NCI )] (UMLS (NCI) C0014922) =Steroid; Pharmacologic Substance ;
=17beta-(estra-1,3,5(10)-triene-3,17-diol 3-[bis(2-chloroethyl)carbamate];
=ESTRAMUSTINE PHOSPHATE SODIUM 140 MG;
|
- 123. ESOPHAGOMYOTOMY
- [ ] (UMLS (ICD9CM) C0192265) =Therapeutic or Preventive Procedure
| - 172. Estramustine Phosphate
- (UMLS (NCI) C0356799) =Steroid; Pharmacologic Substance
|
- 124. esophagoscopy
- [(eh-sof-a-GAHS-ko-pee) Examination of the esophagus using a thin, lighted tube. ( NCI )] (UMLS (NCI) C0014873) =Diagnostic Procedure ;
| - 173. Estramustine/Ixabepilone
- (UMLS (NCI) C1134493) =Therapeutic or Preventive Procedure
|
- 125. ESOPHAGOSCOPY BY INCIS
- [ ] (UMLS (ICD9CM) C0176724) =Diagnostic Procedure
| - 174. Estramustine/Mitoxantrone/Vinorelbine
- (UMLS (NCI) C0879496) =Therapeutic or Preventive Procedure
|
- 126. ESOPHAGOSCOPY NEC
- [ ] (UMLS (ICD9CM) C0176725) =Diagnostic Procedure
| - 175. Estramustine/Paclitaxel/Vinorelbine
- (UMLS (NCI) C0879350) =Therapeutic or Preventive Procedure
|
- 127. Esophagoscopy through artificial stoma
- [ ] (UMLS (ICD9CM) C0192307) =Diagnostic Procedure
| - 176. Estrapronicate
- (UMLS (NCI) C0618602) =Steroid; Pharmacologic Substance; Hormone
|
- 128. esophagostomy
- [Surgical formation of an external opening (stoma) into the esophagus. ( MSH )] (UMLS (CSP) C0014875) =Therapeutic or Preventive Procedure ;
| - 177. Estrasorb
- (UMLS (NCI) C1320235) =Steroid; Pharmacologic Substance; Hormone
|
- 129. ESOPHAGOSTOMY INFECTION
- [ ] (UMLS (ICD9CM) C1456233) Infection of esophagostomy;
=Disease or Syndrome ;
| - 178. estratriene compound
- [ ] (UMLS (CSP) C0178625) =Steroid =Steroid;
=[HS300] ESTROGENS |
- 130. Esophagotomy
- [ ] (UMLS (ICD9CM) C0152461) =Therapeutic or Preventive Procedure
| - 179. estriol
- [oxidation product of estradiol and estrone, having relatively weak estrogenic activity, detectable in high concentration in urine, especially human pregnancy urine. ( CSP )] (UMLS (CSP) C0014927) =Steroid; Pharmacologic Substance; Hormone =[HS300] ESTROGENS;
|
- 131. esophagus
- [portion of the digestive canal between the pharynx and stomach. ( CSP )] (UMLS (NCI) C0014876) =Body Part, Organ, or Organ Component ;
=Body System, Gastrointestinal;
Body Part | - 180. EstroGel
- (UMLS (NCI) C1330258) =Steroid; Pharmacologic Substance; Hormone
|
- 132. esophagus cancer
- [A primary or metastatic malignant neoplasm involving the esophagus ( NCI )] (UMLS (CSP) C0546837) =Neoplastic Process ;
| - 181. estrogen analog
- [synthetic or natural chemical compounds which resemble naturally occurring estrogens in structure and/or function. ( CSP )] (UMLS (CSP) C0014941) =Pharmacologic Substance =sex hormone analog;
=(E)-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol;
(17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol;
Phytoestrogen;
[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone |
- 133. ESOPHAGUS INJURY-CLOSED
- (UMLS (ICD9CM) C1318512) Injury to esophagus without mention of open wound into cavity;
=Injury or Poisoning | - 182. Estrogen Metabolism
- [Estrogen Metabolism consists of diverse biochemical reactions primarily in the ovary that produce 19-carbon steroid hormones, which promote secondary female sexual development and menstrual function or convert such steroids to metabolic derivatives. ( NCI )] (UMLS (NCI) C1158342) =Molecular Function
|
- 134. ESOPHAGUS INJURY-OPEN
- [ ] (UMLS (ICD9CM) C0160342) =Injury or Poisoning
| - 183. ESTROGEN RECEP NEG STAT
- [ ] (UMLS (ICD9CM) C1719707) Estrogen receptor negative status [ER-] =Finding
|
- 135. esophagus motility/pressure
- [movement through the esophagus involving esophageal wall motion and intraluminal pressures. ( CSP )] (UMLS (CSP) C0872041) =Organ or Tissue Function ;
=gastrointestinal motility/pressure;
| - 184. ESTROGEN RECEP PSTV STAT
- [ ] (UMLS (ICD9CM) C1719706) Estrogen receptor positive status [ER+] =Finding
|
- 136. Esophagus necrosis
- (UMLS (NCI) C1404779) Esophagus Necrosis Adverse Event;
=Finding ;
| - 185. Estrogen Receptor Status Unknown
- (UMLS (NCI) C0279758) =Finding
|
- 137. esophagus surgery
- [ ] (UMLS (CSP) C0192259) =Therapeutic or Preventive Procedure
| - 186. estrogen sulfate
- [ ] (UMLS (CSP) C0598401) =Organic Chemical; Pharmacologic Substance; Hormone
|
- 138. Esophagus, Laceration(s) Of
- [A torn, ragged, mangled wound, or an accidental cut of esophagus. ( NCI )] (UMLS (NCI) C0347629) =Injury or Poisoning
| - 187. Estrogen Therapy
- (UMLS (NCI) C0279494) =Therapeutic or Preventive Procedure
|
- 139. ESOPHORIA
- [ ] (UMLS (ICD9CM) C0152216) =Disease or Syndrome ;
| - 188. Estrone Hydrogen Sulfate compound with Piperazine(1:1)
- [A natural estrogenic substance composed of estrone sulfate and piperazine. Estropipate diffuses through the cell membrane and binds to and subsequently activates the nuclear estrogen receptor found in the reproductive tract, breast, pituitary, hypothalamus, liver, and bone. The activated complex binds to the estrogen response element on the DNA and activates the transcription of genes involved in the functioning of the female reproductive system and secondary sex characteristics. ( NCI )] (UMLS (NCI) C0071108) =Steroid; Pharmacologic Substance; Hormone =[HS300] ESTROGENS;
1,3,5(10)-Estratrien-3-ol-17-one;
[GU500] ESTROGENS, VAGINAL;
=ESTROPIPATE 1.5 MG;
ESTROPIPATE 6 MG;
ESTROPIPATE 3 MG;
ESTROPIPATE 0.75 MG;
ESTROPIPATE 1.5 MG/GM |
- 140. Esperamicin A1
- [An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety. Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora. The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04) ( NCI )] (UMLS (NCI) C0082481) =Organic Chemical; Pharmacologic Substance ;
| - 189. Estrone Sodium Sulfate
- (UMLS (NCI) C0304783) =Steroid; Pharmacologic Substance; Hormone =1,3,5(10)-Estratrien-3-ol-17-one;
=ESTRONE SODIUM SULFATE 2.5 MG;
ESTRONE SODIUM SULFATE 0.625 MG |
- 141. ESR/ACK _ Automated equipment status request
- (UMLS (HL7) C1549383) =Health Care Activity =Event Type;
| - 190. Estrone-Sulfate
- [An aqueous substance that is the sulfate salt form of estrone. (NCI) ( NCI )] (UMLS (NCI) C0059668) =Steroid; Pharmacologic Substance; Hormone
|
- 142. ESR1
- [This gene is involved in ligand-activated transcriptional activity. ( NCI )] (UMLS (NCI) C1414461) ESR1 Gene;
Estrogen Receptor 1 Gene =Gene or Genome | - 191. Estrosyn
- (UMLS (NCI) C0699331) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance
|
- 143. ESR2
- [This gene plays a role in extracellular signal transduction that is coupled to transcriptional responses. ( NCI )] (UMLS (NCI) C1414462) ESR2 Gene;
Estrogen Receptor 2 (ER Beta) Gene =Gene or Genome | - 192. estrous
- [recurrent restricted period of sexual receptivity in female mammals other than humans and some nonhuman primates. ( CSP )] (UMLS (CSP) C0014948) =Organism Function =sex cycle;
|
- 144. Essential and other specified forms of tremor
- [ ] (UMLS (ICD9CM) C1961111) TREMOR NEC;
=Sign or Symptom ;
| - 193. Estulic
- (UMLS (NCI) C0733429) =Organic Chemical; Pharmacologic Substance
|
- 145. essential fatty acid
- [long chain organic acid molecules that must be obtained from the diet. ( CSP )] (UMLS (CSP) C0015686) =Lipid; Biologically Active Substance ;
=dietary fat;
Fatty Acids, Unsaturated =Arachidonic Acids;
Linoleic Acids;
Linolenic Acids;
| - 194. ESU/ACK _ Automated equipment status update
- (UMLS (HL7) C1549382) =Health Care Activity =Event Type;
|
- 146. essential hypertension
- [hypertension occurring without preexisting renal disease or known organic cause. ( CSP )] (UMLS (CSP) C0085580) =Disease or Syndrome ;
=Blood Pressure, High;
| - 195. Esuprone
- (UMLS (NCI) C0664097) =Organic Chemical; Pharmacologic Substance ;
|
- 147. Essential or progressive iris atrophy
- (UMLS (ICD9CM) C0271111) =Disease or Syndrome ;
| - 196. ESWL GB/BILE DUCT
- [ ] (UMLS (ICD9CM) C0178190) =Therapeutic or Preventive Procedure
|
- 148. Essential Thrombocytemia
- [clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets. ( CSP )] (UMLS (NCI) C0040028) =Disease or Syndrome =blood coagulation disorder;
Blood Platelet Disorders;
HEMORRHAGIC COND NOS;
Thrombocytosis | - 197. ESWL KID/URETER/BLADDER
- [ ] (UMLS (ICD9CM) C0178189) =Therapeutic or Preventive Procedure
|
- 149. essential thrombocytopenia
- [ ] (UMLS (CSP) C0677060) =Disease or Syndrome
| - 198. ESWL OTHER SITES
- [ ] (UMLS (ICD9CM) C0376100) =Therapeutic or Preventive Procedure
|
home
